MiMedx Recognized as Number 5 on Fortune Magazine’s List of the 100 Fastest Growing Public Companies
MARIETTA, Ga., Sept. 12, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been recognized by Fortune Magazine as the fifth ranked company in Fortune’s 2017 list of the top 100 fastest growing public companies.
The methodology utilized by Fortune Magazine for its ranking of the top 100 fastest growing public companies includes the company must be listed on a major U. S. stock exchange; have a minimum market capitalization of $250 million and a stock price of at least $5 on June 30, 2017; and have been trading continuously since June 30, 2014. These companies must have revenue and net income for the four quarters ended on or before April 30, 2017 of at least $50 million and $10 million, respectively; and have posted an annualized growth in revenue and earnings per share (EPS) of at least 15% annually over the three years ended on or before April 30, 2017.
Companies that meet these criteria are ranked by revenue growth rate, EPS growth rate, and three-year annualized total return for the period ended June 30, 2017. Fortune determines the overall rank based on the sum of the three ranks. Once the 100 companies are identified, they are then re-ranked within the 100, using these three equally weighted variables.
Parker H. “Pete” Petit, Chairman and CEO stated, “We are pleased to be among the top 100 companies in this prestigious group, and we are extremely honored to be ranked number 5. This recognition is a tribute to the outstanding employees who comprise the MiMedx team and the remarkable healing capabilities of the regenerative medicine products we offer. We are pleased that our dehydrated human amnion chorion membrane (dHACM) allografts are playing an expanding role in helping the healthcare community to improve clinical outcomes and reduce costs.”
About MiMedx
MiMedx® is a biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
Important Cautionary Statement
This press release includes forward-looking statements, including statements regarding the remarkable healing capabilities of the regenerative medicine products the Company offers and the expanding role played by the Company in helping the healthcare community improve clinical outcomes and reduce costs. These statements also may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that the healing capabilities of the Company’s products may not continue to have the same results and the Company may not continue to play an expanding role in helping the healthcare community improve clinical outcomes and reduce costs. For more detailed information on the risks and uncertainties associated with new product development and commercialization activities, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.
SOURCE MiMedx Group, Inc.
